PYC Therapeutics LimitedASX: PYC

PKD Program - Enrolment Target Met

· Issued by PYC Therapeutics Limited via ASX

Filed with ASX · · 3 pages · English

Release

13 November 2026 POLYCYSTIC KIDNEY DISEASE PROGRAM – ENROLMENT TARGET MET • PYC is a precision medicine company dedicated to changing the lives of patients with genetic diseases who have no treatment options available • The Company is progressing a drug candidate (known as PYC-003) that...

PYC Therapeutics Limited on 6ix

In the deck

Earlier from PYC Therapeutics

All PYC Therapeutics news releases